AzTrials
AzTrials

Skin Barrier FunctionNCT07896993

Mask Instant Clinical Study

A study testing Test soothing facial mask in people with Skin Barrier Function and Skin Soothing Effect, run by ChinaNorm at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical study is to evaluate the soothing effect of the test product within 2 hours after a single application by measuring changes in multiple indicators before and after product use. It will also assess the safety of the test product. Read more about this study

Who is it for?
Ages 25 to 45 years, women onlyHealthy volunteers can take part
Conditions the study is for
Skin Barrier Function, Skin Soothing Effect
What is being tested?
Test soothing facial mask
Could I receive a placebo?
No, everyone receives an active treatment
How many people
35 participants
Where
1 siteChina
Study dates
12 Jun 2026to 30 Jun 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 45 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • 1. Chinese female, 25-45 years old. 2. Self-declare mild sensitive skin. 3. Self-declare with skin concerns of redness and easy to flush. 4. Willing to be exposed to infrared light on the facial area to induce facial redness.
  • 5. Presenting with corresponding severity for the attribute evaluated by Dermatologist included:
  • ◼ Skin redness after infrared light induction (7-8 min): grade ≥4 (0-9 scale). 6. All accept not to use any cosmetics, skincare products, beauty equipment, and all topical medications on the face within 72 hours prior to the study and on the visit day before coming to the lab, except for a cleanser. 7. Did not participate in any clinical test or cosmetic product test on skin within 1 month.
  • 8. No disagreement of dermatologist because of other reasons that exclude the participation of the volunteer. 9. In general, good health at the time of the study. 10. Willing and able to participate as evidenced by signing of informed consent and photo release form.
  • 11. Must be willing to comply with all study protocol requirements.

Who cannot join

  • 1. Pregnant or breast-feeding woman or woman planning pregnancy during the study.
  • 2. Subject deprived of rights by a court or administrative order. 3. Major subject to a guardianship order. 4. Subject residing in a health or social care establishment. 5. Patient in an emergency setting. 6. Volunteer with a skin disease in the test areas as well as skin allergy (particularly e.g., acne, rosacea, eczema). 7. Volunteer presenting a stable or progressive serious disease (per investigator's assessment).
  • 8. Immuno-compromised subject. 9. Subject with history of allergy to cosmetic or personal care products or ingredients.
  • 10. Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment).
  • 11. Subject with history of sunlight sensitivity or allergies. 12. Subjects regularly practicing aquatic or nautical sports. 13. Subjects regularly attending a sauna. 14. Subject with physical highly sensitive constitution. 15. Subject with cardiovascular or circulatory history. 16. Subject with a history of skin cancer or malignant melanoma. 17. Subject with history of medical beauty treatment and taking part in other studies in the last 6 months before study. 18.Use of antihistamines, antibiotics, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), or immunosuppressants within 6 months prior to the study.

Trial locations and contacts

1 site in 1 country.

China1 site
  • Shanghai China-norm Quality Technical Service Co., Ltd., Shanghai, Shanghai 200072, Shanghai,

    Shanghai, Shanghai Municipality

Other trials in China

About this study

The goal of this clinical study is to evaluate the soothing effect of the test product within 2 hours after a single application by measuring changes in multiple indicators before and after product use. It will also assess the safety of the test product. The main questions it aims to answer are:

  • Does the test product relieve skin irritation and reduce skin redness within 2 hours after single use?
  • What adverse skin reactions do participants experience after using the test product?
Read more

Researchers will compare the treated half-face with the untreated contralateral half-face (split-face control) to verify the soothing efficacy of the test product.

Participants will:

  • Receive skin redness induction on both cheeks, then apply the test product on one side of the face
  • Undergo skin assessments at baseline before redness induction, post-induction, and at 10 seconds, 1 minute, 5 minutes, 10 minutes, 1 hour and 2 hours after product application
  • Complete clinical evaluation, instrumental measurement, image analysis and self-assessment questionnaires at each time point
Being tested
Test soothing facial mask

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Test soothing facial maskOther

    Facial mask containing panthenol and madecassoside, applied on one hemiface for 15 minutes in single use after erythema induction.

Study groups in NCT07896993
Study groupRoleWhat they receive
Arm A :Test Facial Mask SideExperimentalTest half-face treatment: after skin erythema induction, trained investigator applies half-piece test facial mask on randomly assigned hemiface, kept for 15 minutes then removed.
Receives: Other: Test soothing facial mask
Arm B :Control SideNo interventionControl half-face treatment: after skin erythema induction, no mask or test product applied on the contralateral hemiface.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Erythema index measured by Mexameter MX18

    Skin erythema index of the hemiface will be measured by Mexameter MX18. Three consecutive valid readings will be taken and averaged for each measurement.

    Measured: BL (before infrared induction), T0 (immediately after induction), 10 minutes, 1 hour and 2 hours after induction

Secondary outcomes (4)
  1. Dermatologist clinical assessment of skin redness

    Dermatologists perform clinical assessment of skin redness using modified Griffiths 10-point scale (0-9, half-point increments allowed). Whenever possible, the same dermatologist assesses the same participant; the rater is not permitted to refer to previous scores for post-baseline evaluations.

    Measured: BL (before infrared induction), T0 (immediately after induction), 10 minutes, 1 hour and 2 hours after induction

  2. VISIA-CR facial photography

    Standardized facial images (front, left, right) are captured under 4 lighting modes including standard light 1, standard light 2, cross polarized and parallel polarized light.

    Measured: BL (before infrared induction), T0 (immediately after induction), 10 minutes, 1 hour and 2 hours after induction

  3. TiVi700 measurement of skin microcirculation

    TiVi700 captures skin microvascular red blood cell concentration (TiVi index) on bilateral cheek regions to assess cutaneous microcirculation status.

    Measured: BL (before infrared induction), T0 (immediately after induction), 10 minutes, 1 hour and 2 hours after induction

  4. Subject self-assessment questionnaire for skin sensory symptoms

    Subjects self-grade stinging, itching, burning and tightness on a 0-4 intensity scale. Score 0 = none; Score 1 = very slight; Score 2 = slight; Score3 = moderate; Score4 = severe.

    Measured: 10 minutes, 1 hour and 2 hours after infrared induction

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Oct 2026
  2. Study start12 Jun 2026
  3. Primary completion15 Jun 2026
  4. Study completion30 Jun 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
35 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07896993
Sponsor's protocol ID
C26005061
Status last verified
Oct 2026
First submitted
20 Oct 2026
Last updated
27 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Test soothing facial mask in people with Skin Barrier Function and Skin Soothing Effect, run by ChinaNorm at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Erythema index measured by Mexameter MX18 (time frame: BL (before infrared induction), T0 (immediately after induction), 10 minutes, 1 hour and 2 hours after induction). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026; AzTrials last refreshed its copy on 28 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in